Compare LCTX & FCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCTX | FCEL |
|---|---|---|
| Founded | 1990 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 398.1M |
| IPO Year | N/A | 1992 |
| Metric | LCTX | FCEL |
|---|---|---|
| Price | $1.65 | $8.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | $4.25 | ★ $9.08 |
| AVG Volume (30 Days) | 1.3M | ★ 2.8M |
| Earning Date | 11-06-2025 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,816,000.00 | ★ $158,162,000.00 |
| Revenue This Year | $6.32 | $15.27 |
| Revenue Next Year | $124.49 | $37.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.05 | ★ 41.05 |
| 52 Week Low | $0.37 | $3.58 |
| 52 Week High | $2.09 | $13.98 |
| Indicator | LCTX | FCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 53.21 |
| Support Level | $1.63 | $7.95 |
| Resistance Level | $1.77 | $9.25 |
| Average True Range (ATR) | 0.08 | 0.81 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 16.67 | 23.06 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.